Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CRAWSHAW GROUP PLC. We currently have 3 research reports from 1 professional analysts.
|17Feb17 10:10||RNS||Holding(s) in Company|
|09Jan17 17:04||RNS||Holding(s) in Company|
|06Jan17 07:00||RNS||Trading Statement|
|19Dec16 15:20||RNS||Holding(s) in Company|
|29Nov16 07:00||RNS||Trading update|
|17Nov16 07:00||RNS||Block listing Interim Review|
|12Oct16 16:10||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
CRAWSHAW GROUP PLC
CRAWSHAW GROUP PLC
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
15 Sep 16
COLEFAX GROUP PLC (CFX LN) | COLLAGEN SOLUTIONS PLC (COS LN) | CRAWSHAW GROUP PLC (CRAW LN) | CRONIN GROUP PLC (CRON LN) | FRANCHISE BRANDS PLC (FRAN LN) | INFRASTRUCTURE INDIA PLC (IIP LN) | MEDAPHOR GROUP PLC (MED LN) | POWERFLUTE OYJ (POWR LN) | PURPLEBRICKS GROUP PLC (PURP LN) | TRIBAL GROUP PLC (TRB LN)
Roughly in line with our expectations
23 Feb 17
JM announced FY 16 net result of €593m, of which €232m related to the Moterrorio disposal as exceptional items. The EBITDA margin increased to 5.9%, boosted by the good resilience of Biedronka’s profitability. The cash flow situation improved, leading to a negative net debt. Thanks to stronger cash flow generation, the company proposed a €0.60 dividend per share (flat compared to last year, including the distribution of free reserves of €0.375 per share).
N+1 Singer - Conviviality - Delivering against strategy
30 Jan 17
Interims are robust and broadly in line with our expectations. The 4.4% LFL sales growth and positive KPI’s on customer wins and higher spend per outlet demonstrate that the strategy is working. H2 has started very well with good momentum across all 3 divisions as the new MD’s begin to have a positive impact. With PBT 2/3rd H2-biased we make no major forecast changes but see the risk on the upside. The shares are up 21% YTD but given the positive overall tenor and valuation read-across from the Booker/Tesco deal (24.5x P/E), CVR remains inexpensive on a cal’17 P/E of 11.2x with a 5% DPS yield and a 3 year EPS CAGR of 24%. We stay at Buy with a 290p TP.
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
Have investors checked out too early?
26 Feb 16
While some of the share price decline from 8p in December can be attributed to dilution from the placing announced that month and general market risk aversion, the current market cap of c.£8m appears not to recognise the progress in establishing a global brand, a range of unique accommodation formats and an ever expanding event programme, moving towards profitability and with exciting prospects.